This is where you will find information on the latest updates to the National Clinical Terminology Service products and resources. The details of any changes are included in the relevant release note.
|/library/DH_3332_2020_ClinicalTerminology_SNOMEDCT-AU_ReleaseNote_v20201031.pdf||SNOMED CT-AU Release Note 31 October 2020|
|/library/DH_3333_2020_NCTS_DocumentLibraryReleaseNote_v2.24.pdf||NCTS Document Library Release Note v2.24|
|/library/DH_3319_2020_RCPA_PathologyTerminologyandInformationModels_ReleaseNote_v1.4.pdf||RCPA Pathology Terminology and Information Models Release Note v1.4|
Document Library update
The following document has been added to the Document Library:
- AMT Editorial Rules v2.8
- Terminology Requirements for Electronic Prescriptions and Active Ingredient Prescribing presentation
- Terminology Requirements for Electronic Prescriptions and Active Ingredient Prescribing webinar
- Linking AMT and GTIN: Project Requirements for Pharmaceutical Suppliers presentation v1.1
- Linking AMT and GTIN: Project Requirements for Pharmaceutical Suppliers webinar
Please refer to the NCTS Document Library Release Note v2.24 above for further details.
RCPA – Pathology Terminology and Information models
The Royal College of Pathologists of Australasia (RCPA) pathology terminology and information model resources have been updated to v1.4. This package contains the addition of a Blood Gas Terminology Reference Set and updated LOINC licensing information for previously published files. The zip file can be downloaded here.
New and updated Third Party reference sets
List of Medicines for Brand Consideration reference set
Produced by the Australian Government Department of Health, this reference set enables software vendors to identify AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) under The National Health (Pharmaceutical Benefits) Amendment (Active ingredient Prescribing) Regulations 2019 and The Veterans’ Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019.
Electronic Recording and Reporting of Controlled Drugs (ERRCD)
The following reference sets have been expanded to include AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP). Only the refset content has been expanded with no change to the existing format and the word ‘trade’ has been removed from the refset name.
- Schedule 8 medications;
- South Australia reportable Schedule 4 medications;
- Tasmania reportable Schedule 4 medications;
- Victoria reportable Schedule 4 medications; and
- Queensland Health QScript Schedule 4 monitored medicines
The following list contains all COVID-19 specific concepts that are currently available in the SNOMED CT-AU release. They are displayed below as concept ID |Preferred Term| and grouped according to their SNOMED CT concept hierarchy. You can view any additional synonyms to these concepts in the Shrimp Terminology Browser. If you have suggestions for new concepts or synonyms, please complete our online request form (preferred) or send your content request to email@example.com.
1454671000168104 |Recent travel to high risk COVID-19 region|
1465981000168100 |Bilateral interstitial pneumonia| added May 2020
1466021000168105 |Concern about exposure to COVID-19| added May 2020
1466151000168103 |More than two diffuse B-lines on ultrasound of lung| added May 2020
840544004 |Suspected COVID-19|
840546002 |Exposure to COVID-19|
840533007 |SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)|
840534001 |COVID-19 vaccination|
1454651000168108 |COVID-19 serology|
1454581000168100 |Bronchoalveolar lavage fluid COVID-19 nucleic acid assay|
1454561000168109 |Sputum COVID-19 nucleic acid assay|
1454491000168101 |Oropharyngeal swab COVID-19 nucleic acid assay|
1454411000168105 |Nasopharyngeal swab COVID-19 nucleic acid assay|
1454401000168107 |Home isolation|
1462681000168102 |Rapid COVID-19 antibody detection test|
1462701000168104 |COVID-19 IgM measurement|
1462741000168102 |COVID-19 IgG measurement|
1466171000168107 |ARDSNet Mechanical Ventilation Protocol| added May 2020
1466161000168101 |Permissive hypercapnia ventilation| added May 2020
1466191000168108 |Pleural fluid COVID-19 nucleic acid assay| added May 2020
1466181000168105 |Saliva COVID-19 nucleic acid assay| added May 2020
1480481000168103 | COVID-19 viral culture | added July 2020
1454661000168105 |COVID-19 Clinic and Testing Centre|
840536004 |Antigen of SARS-CoV-2|
840535000 |Antibody to SARS-CoV-2|
Containered Trade Product Pack (Australian Medicines Terminology)
1480881000168101 | Veklury 100 mg powder for injection, 1 vial | added July 2020
1480791000168108 | Veklury 100 mg/20 mL injection, 20 mL vial | added July 2020
By operation of the Public Governance, Performance and Accountability (Establishing the Australian Digital Health Agency) Rule 2016, on 1 July 2016, all the assets and liabilities of NEHTA will vest in the Australian Digital Health Agency. In this website, on and from 1 July 2016, all references to “National E-Health Transition Authority” or “NEHTA” will be deemed to be references to the Australian Digital Health Agency.